• Home
  • Search Results
  • Novel CH1:CL interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies.

Novel CH1:CL interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies.

Protein engineering, design & selection : PEDS (2017-10-06)
Maximilian Bönisch, Carolin Sellmann, Daniel Maresch, Claudia Halbig, Stefan Becker, Lars Toleikis, Björn Hock, Florian Rüker

Targeting two unique antigens with a single bispecific antibody is an attractive approach with potential broad therapeutic applicability. However, the production of heterodimeric bispecific antibodies (bsAbs) presents a challenge, requiring the co-expression and accurate pairing of two distinct heavy and light chain units. Several undesirable by-products can be formed in the production process, including heavy chain homodimers and non-cognate light chain pairings. Although additional downstream purification methods exist, they are often time consuming and restrict practical large-scale production. In this study, we identify and validate novel Fab interface mutations that increase cognate light chain pairing efficiencies within heterodimeric bsAbs. Importantly, the variable domains remain unaltered as interface mutations were restricted to the CH1 and CL domains. We performed several biochemical assays to demonstrate that the novel engineered interfaces do not adversely impact bispecific antibody expression, stability, affinity and biological function. The designs reported here can easily be applied in a generic manner to use existing antibodies as building blocks for bsAbs which will help to accelerate the identification and production of next generation bispecific antibody therapeutics.

Product Number
Product Description

3,3′,5,5′-Tetramethylbenzidine (TMB) Liquid Substrate System for ELISA, peroxidase substrate
Anti-Human IgG (Fc specific)−Peroxidase antibody produced in goat, affinity isolated antibody
Anti-Human IgG (Fc specific), F(ab′)2 fragment antibody produced in goat, affinity isolated antibody, buffered aqueous solution

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.